Immunotherapy combination induces ‘robust’ responses in high-risk follicular lymphoma

SAN DIEGO — Limited duration loncastuximab tesirine in addition to rituximab appeared well tolerated and highly effective for relapsed or refractory follicular lymphoma, according to data presented at ASH Annual Meeting and Exposition.
“We observed that limited duration loncastuximab with rituximab drives significant complete metabolic response rate in patients with relapsed or refractory follicular lymphoma with high-tumor burden and [progression of disease within 24 months (POD24)],” Juan Pablo Alderuccio, MD, associate professor of medicine in the division of hematology at

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart